These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26018435)

  • 21. Osteoprotegerin-deficient male mice as a model for severe alveolar bone loss: comparison with RANKL-overexpressing transgenic male mice.
    Koide M; Kobayashi Y; Ninomiya T; Nakamura M; Yasuda H; Arai Y; Okahashi N; Yoshinari N; Takahashi N; Udagawa N
    Endocrinology; 2013 Feb; 154(2):773-82. PubMed ID: 23291450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct effects of osteoprotegerin on human bone cell metabolism.
    Grundt A; Grafe IA; Liegibel U; Sommer U; Nawroth P; Kasperk C
    Biochem Biophys Res Commun; 2009 Nov; 389(3):550-5. PubMed ID: 19748486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin.
    Luan X; Lu Q; Jiang Y; Zhang S; Wang Q; Yuan H; Zhao W; Wang J; Wang X
    J Immunol; 2012 Jul; 189(1):245-52. PubMed ID: 22664871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
    Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
    Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis.
    Moreno-Rubio J; Herrero-Beaumont G; Tardio L; Alvarez-Soria MA; Largo R
    Arthritis Rheum; 2010 Feb; 62(2):478-88. PubMed ID: 20112374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
    Nakamura M; Udagawa N; Matsuura S; Mogi M; Nakamura H; Horiuchi H; Saito N; Hiraoka BY; Kobayashi Y; Takaoka K; Ozawa H; Miyazawa H; Takahashi N
    Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse.
    Mori H; Kitazawa R; Mizuki S; Nose M; Maeda S; Kitazawa S
    Histochem Cell Biol; 2002 Mar; 117(3):283-92. PubMed ID: 11914926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TNFα but not IL-17 is critical in the pathogenesis of rheumatoid arthritis spontaneously occurring in a unique FcγRIIB-deficient mouse model.
    Okazaki H; Lin Q; Nishikawa K; Ohtsuji N; Tsurui H; Ohtsuji M; Amano H; Tada N; Sudo K; Nishimura H; Shirai T; Hirose S
    Mod Rheumatol; 2014 Nov; 24(6):931-8. PubMed ID: 24593165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoprotegerin and inflammation.
    Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC
    Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.